Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase Ib Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Seres Therapeutics, Inc. announced that enrollment in Cohort 2 in its SER-155 Phase Ib study was underway. SER-155, an investigational oral microbiome therapeutic, was designed to reduce the incidence of gastrointestinal infections, bloodstream infections, and graft versus host disease in individuals undergoing allogeneic hematopoietic stem cell transplantation.